The Cocktail Report (sound really smart around your friends):
Life Biosciences has released the first human data on ER-100, a gene therapy that turns on three cell-resetting genes inside the eye.
Three adults with open-angle glaucoma each got one eye injection, then took a daily antibiotic pill for 56 days to switch the genes on.
The company reported zero serious adverse events and zero dose-limiting side effects through day 56.
In two of the three patients, at least 28% of the spots checked on a vision-field exam got better by more than 4 decibels.
An independent safety board approved moving up to a dose three times larger.
If you have glaucoma, or watched a parent lose side vision to it, you have probably heard that the damage cannot be undone. On October 8, 2026, the first people given a therapy built to challenge that rule got their first report card.
Life Biosciences, a Boston biotech, presented early data from its Phase 1 trial of ER-100 at Eyecelerator, a meeting held with the American Academy of Ophthalmology in New Orleans [1]. It is the first human readout for partial epigenetic reprogramming, a method that resets the chemical tags deciding which genes a cell keeps switched on.
How the treatment works
ER-100 carries three genes, OCT4, SOX2, and KLF4 (together called OSK), into the eye inside AAV2, a harmless virus stripped down to work as a delivery vehicle. The genes stay quiet until the patient takes doxycycline, a common antibiotic that acts as the on switch, for 8 weeks.
The target is the retinal ganglion cell, the nerve cell wiring each eye to the brain. These cells do not grow back, which is why glaucoma damage has been treated as permanent.
What happened in the first three patients
Each of the three adults with open-angle glaucoma received one injection into the gel that fills the eye, at the lowest planned dose of 2x10^11 viral copies [1]. They also took a tapering course of prednisolone, a steroid, to calm any immune reaction to the virus.
Through day 56, the company reported no dose-limiting toxicities, no serious adverse events, and no adverse events of special interest. Every side effect that did show up was tied to the injection itself, the steroid, or a condition the patient already had.
The trial's Data Safety Monitoring Board, an outside panel that must sign off before doses rise, recommended stepping up to 6x10^11 copies. That is three times the starting dose.
The vision signal
The team also ran the Humphrey visual field test, which flashes small lights across your field of view and scores, in decibels, how faint a light you can still catch [1]. Two of the three patients improved by day 56, and in each of them at least 28% of the tested spots gained more than 4 decibels.
If you are being treated for glaucoma, ask your eye doctor for your "mean deviation," the single summary number from that same test. This trial only took people scoring between -6 and -20 dB, which counts as moderate to advanced loss.
Who the trial is for
The registry plans up to 18 people: 12 with glaucoma and 6 with NAION (non-arteritic anterior ischemic optic neuropathy), a sudden, painless vision loss caused by poor blood flow to the optic nerve. Participants must be 40 to 85, and they return once a year through year 5.
The company calls NAION the most common sudden optic nerve disorder in adults over fifty, and no treatment for it is approved. Main data collection is expected to finish in May 2027.
What this does and does not show
To be frank, three patients cannot tell anyone whether a treatment works. The trial is open-label, meaning everyone knows who got the drug, and it has no comparison group.
All of these results are company-reported from a conference talk, not a peer-reviewed paper. The trial's main goals are safety and tolerability, so the vision gains are an early side signal, and the treatment is available only inside the study.
Why Should You Care?
For the first time, a therapy meant to make old cells act younger has gone into human eyes without serious harm over its first eight weeks. If the stronger dose holds up and more patients see gains, glaucoma loss may stop being a one-way street.
1. Life Biosciences. "Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies." GlobeNewswire, October 8, 2026. https://www.globenewswire.com/news-release/2026/10/08/3377649/0/en/life-biosciences-announces-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies.html
2. ClinicalTrials.gov. "A Phase 1 Single Dose Study to Evaluate the Safety and Tolerability of ER-100 in Optic Neuropathies [Open Angle Glaucoma (OAG) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)]." NCT07290244. https://clinicaltrials.gov/study/NCT07290244
